Revelation Biosciences reported better-than-expected Q1 earnings, which could lead to a positive short-term impact on the stock price. The company beat earnings estimates by 21.54%, which is a significant margin. However, revenue remained unchanged from the same period last year, which may limit the stock's upside potential.